ArticleMicrobial cell factories2020
Exploiting bacterial outer membrane vesicles as a cross-protective vaccine candidate against avian pathogenic Escherichia coli (APEC).
Article in Microbial cell factories, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Pooled it
- A systematic review and meta-analysis on the efficacy of vaccination against colibacillosis in broiler production.PloS one · 2024Pooled it
- Bacterial Membrane Vesicles as Versatile Platforms for Systemic and Mucosal Vaccines.Vaccines · 2026Review
- Frontiers in bacterial outer membrane vesicles: From basic characteristics to cancer therapy.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Outer Membrane Vesicles as a Versatile Platform for Vaccine Development: Engineering Strategies, Applications and Challenges.Journal of extracellular vesicles · 2025Review
- Bioengineering Outer-Membrane Vesicles for Vaccine Development: Strategies, Advances, and Perspectives.Vaccines · 2025Review
- Separation and Characterization of Heterogeneity Among Various Sizes of Outer Membrane Vesicles Derived from the ProbioticMembranes · 2025Article
- Serogrouping and Molecular Characterization of ESBL-Producing Avian PathogenicAntibiotics (Basel, Switzerland) · 2025Article
- Outer membrane vesicles derived from probioticFrontiers in immunology · 2025Article
- Avian pathogenicVeterinary world · 2024Review
- Development of High-Production Bacterial Biomimetic Vesicles for Inducing Mucosal Immunity Against Avian PathogenicInternational journal of molecular sciences · 2024Article
- Bacterial extracellular vesicles: biotechnological perspective for enhanced productivity.World journal of microbiology & biotechnology · 2024Review
- Outer membrane vesicles as a platform for the discovery of antibodies to bacterial pathogens.Applied microbiology and biotechnology · 2024Review
- Extracellular vesicles of the probiotic bacteria E. coli O83 activate innate immunity and prevent allergy in mice.Cell communication and signaling : CCS · 2023Article
- Extracellular vesicles produced by avian pathogenic Escherichia coli (APEC) activate macrophage proinflammatory response and neutrophil extracellular trap (NET) formation through TLR4 signaling.Microbial cell factories · 2023Article
- Outer-Membrane Vesicles ofMicroorganisms · 2023Article
- The Diversity ofMicroorganisms · 2023Review
- Opportunities for engineering outer membrane vesicles using synthetic biology approaches.Extracellular vesicles and circulating nucleic acids · 2023Article
- Contamination of bacterial extracellular vesicles (bEVs) in human urinary extracellular vesicles (uEVs) samples and their effects on uEVs study.Journal of extracellular biology · 2022Article
- Engineering bacterial membrane nanovesicles for improved therapies in infectious diseases and cancer.Advanced drug delivery reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundThe well-known fact that avian pathogenic Escherichia coli (APEC) is harder to prevent due to its numerous serogroups has promoted the development of biological immunostimulatory materials as new vaccine candidates in poultry farms. Bacterial outer membrane vesicles (OMVs), known as spherical nanovesicles enriched with various immunostimulants, are naturally secreted by Gram-negative bacteria, and have gained much attention for developing effective vaccine candidates. Recent report has demonstrated that OMVs of APEC O78 can induce protective immunity in chickens. Here, a novel multi-serogroup OMVs (MOMVs) vaccine was developed to achieve cross-protection against APEC infection in broiler chickens.
resultsIn this study, OMVs produced by three APEC strains were isolated, purified and prepared into MOMVs by mixing these three OMVs. By using SDS-PAGE and LC-MS/MS, 159 proteins were identified in MOMVs and the subcellular location and biological functions of 20 most abundant proteins were analyzed. The immunogenicity of MOMVs was evaluated, and the results showed that MOMVs could elicit innate immune responses, including internalization by chicken macrophage and production of immunomodulatory cytokines. Vaccination with MOMVs induced specific broad-spectrum antibodies as well as Th1 and Th17 immune responses. The animal experiment has confirmed that immunization with an appropriate dose of MOMVs could not cause any adverse effect and was able to reduce bacteria loads and pro-inflammatory cytokines production, thus providing effective cross-protection against lethal infections induced by multi-serogroup APEC strains in chickens. Further experiments indicated that, although vesicular proteins were able to induce stronger protective efficiency than lipopolysaccharide, both vesicular proteins and lipopolysaccharide are crucial in MOMVs-mediated protection.
conclusionsThe multi-serogroup nanovesicles produced by APEC strains will open up a new way for the development of next generation vaccines with low toxicity and broad protection in the treatment and control of APEC infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.